Alternative splicing of TIA‐1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance
Open Access
- 20 August 2014
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 9 (1), 167-178
- https://doi.org/10.1016/j.molonc.2014.07.017
Abstract
The angiogenic capability of colorectal carcinomas (CRC), and their susceptibility to anti‐angiogenic therapy, is determined by expression of vascular endothelial growth factor (VEGF) isoforms. The intracellular protein T‐cell Intracellular Antigen (TIA‐1) alters post‐transcriptional RNA processing and binds VEGF‐A mRNA. We therefore tested the hypothesis that TIA‐1 could regulate VEGF‐A isoform expression in colorectal cancers. TIA‐1 and VEGF‐A isoform expression was measured in colorectal cancers and cell lines. We discovered that an endogenous splice variant of TIA‐1 encoding a truncated protein, short TIA‐1 (sTIA‐1) was expressed in CRC tissues and invasive K‐Ras mutant colon cancer cells and tissues but not in adenoma cell lines. sTIA‐1 was more highly expressed in CRC than in normal tissues and increased with tumour stage. Knockdown of sTIA‐1 or over‐expression of full length TIA‐1 (flTIA‐1) induced expression of the anti‐angiogenic VEGF isoform VEGF‐A165b. Whereas flTIA‐1 selectively bound VEGF‐A165 mRNA and increased translation of VEGF‐A165b, sTIA‐1 prevented this binding. In nude mice, xenografted colon cancer cells over‐expressing flTIA‐1 formed smaller, less vascular tumours than those expressing sTIA‐1, but flTIA‐1 expression inhibited the effect of anti‐VEGF antibodies. These results indicate that alternative splicing of an RNA binding protein can regulate isoform specific expression of VEGF providing an added layer of complexity to the angiogenic profile of colorectal cancer and their resistance to anti‐angiogenic therapy.Keywords
Funding Information
- Association for International Cancer Research
- Cancer Research UK (KS, CF11392/A8451, CHA, C11392/A10484)
- Medical Research Council (MR/K020366/1)
- Oxford Comprehensive Biomedical Research Centre
- British Heart Foundation
- North Bristol Specific Cancer Project Fund
- Richard Bright VEGF-A Research Trust
This publication has 30 references indexed in Scilit:
- The binding of TIA-1 to RNA C-rich sequences is driven by its C-terminal RRM domainRNA Biology, 2014
- Three RNA Recognition Motifs Participate in RNA Recognition and Structural Organization by the Pro-Apoptotic Factor TIA-1Journal of Molecular Biology, 2012
- WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF SplicingCancer Cell, 2011
- Alternative splicing of the neurofibromatosis type I pre-mRNABioscience Reports, 2011
- The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal CancerThe Oncologist, 2009
- VEGF-A splicing: the key to anti-angiogenic therapeutics?Nature Reviews Cancer, 2008
- p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosisInternational Journal of Cancer, 2008
- TIA-1 and TIAR Activate Splicing of Alternative Exons with Weak 5′ Splice Sites followed by a U-rich Stretch on Their Own Pre-mRNAsOnline Journal of Public Health Informatics, 2001
- The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNAMolecular Endocrinology, 1991
- Neoplastic transformation of a human colonic epithelial cell line: in vitro evidence for the adenoma to carcinoma sequence.1990